Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs

European Journal of Pharmacology
P BessinJ Benveniste


Synthetic platelet-activating factor (PAF-acether) was shown to act as a shock inducer when a dose of 9 or 36 nmol . kg-1 was injected i.v. into dogs anesthetized with 30 mg . kg-1 i.v. sodium pentobarbitone. Nine nmol . kg-1 PAF-acether caused portal vein and pulmonary artery hypertension but only transiently; blood TXB2 and 6 keto PGF1 alpha levels rose; there was a lasting fall of 77% in systemic blood pressure, cardiac output fell by 86%, heart rate by 17%, plasma volume by 43%, and femoral artery blood flow by 66%, whereas the hematocrit rose by 33%. A dose of 36 nmol . kg-1 PAF-acether reduced coronary artery blood flow by 56%, diminished myocardial O2 consumption, raised O2 extraction and caused metabolic acidosis leading to death in 2 out of 7 animals. All these changes displayed the typical features of common acute circulatory collapse with distributive and hypovolemic etiologies, suggesting that PAF-acether might be an endogenous mediator in the early and late stages of shock.


Jun 28, 1979·Nature·M ChignardJ Benveniste
Jan 1, 1977·Acta Anaesthesiologica Scandinavica·K Pavek
Sep 1, 1976·The Journal of Clinical Investigation·J L WeissM L Weisfeldt
Jan 1, 1976·The American Journal of Physiology·E L CarlsonJ I Hoffman
Oct 1, 1971·Advances in Experimental Medicine and Biology·M H Weil, H Shubin
Apr 1, 1960·Physiological Reviews·R P GILBERT
Oct 1, 1962·The American Journal of Physiology·L B HINSHAWC M BRAKE
Dec 1, 1950·The Journal of Clinical Investigation·S J GRAY, K STERLING


Aug 1, 1991·Annals of Neurology·P J LindsbergG Feuerstein
Oct 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·G L StahlA M Lefer
May 1, 1991·Digestive Diseases and Sciences·C Zhang, W Hsueh
Mar 1, 1990·Agents and Actions·Y DenizotJ Benveniste
Dec 1, 1991·Lipids·R RabinoviciG Feuerstein
Feb 26, 1985·European Journal of Pharmacology·Z TerashitaS Sumida
Jun 10, 1988·European Journal of Pharmacology·J LefortB B Vargaftig
Jan 3, 1991·European Journal of Pharmacology·F SquadritoA P Caputi
Dec 21, 1993·European Journal of Pharmacology·K TakekoshiS Shimoda
Aug 22, 1994·European Journal of Pharmacology·G EmanuelliG Camussi
Oct 1, 1992·Toxicon : Official Journal of the International Society on Toxinology·A YaraM Sakanashi
Jul 1, 1986·Prostaglandins·J L Wallace, B J Whittle
Jan 1, 1988·Molecular Aspects of Medicine·N C OlsonC E McCall
Feb 1, 1985·Immunopharmacology·P IñarreaM Sánchez-Crespo
Jan 1, 1986·Prostaglandins, Leukotrienes, and Medicine·J MehtaW W Nichols
Mar 1, 1987·Prostaglandins, Leukotrienes, and Medicine·R L HébertG E Plante
Apr 1, 1991·Trends in Cardiovascular Medicine·M R HollandS M Prescott
Apr 12, 2001·Journal of Ethnopharmacology·I JantanN A Warif
Mar 1, 1997·Journal of Lipid Mediators and Cell Signalling·G FeuersteinS Vonhof
May 9, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Y Asai, S Watanabe

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.